Rubraca (rucaparib) [package insert]. FDA.

Regulatory approval published by the Food and Drug Administration. Deprecated

Citation

Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf. Revised December 2025. Accessed October 6, 2026.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy.	4

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies
FDA (1)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Rucaparib
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Rucaparib
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Rucaparib
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Rucaparib